22nd Mar 2019 10:15
LONDON (Alliance News) - Renalytix AI PLC on Friday announced the set up of a core investigator group for a kidney transplant diagnostic programme.
Renalytix, which develops artificial intelligence diagnostics for kidney disease, said the group includes "leading" transplant clinicians from Emory University, the University of Manitoba, Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai.
The group will support clinical and regulatory pathways for a portfolio of kidney transplant products known as FractalDx, which will become part of Renalytix's pipeline.
Shares were untraded on Friday, last closing at 137.50 pence each.
Barbara Murphy, who chairs Renalytix's advisory board, said: "Our hope is FractalDx will give us the ability to tailor immunosuppressive therapy to the personal needs of the patient. The current therapeutic practice of 'one size fits all' dosing results in unnecessary complications including infection, cancers or avoidable rejections.
"We have the technology to support development of a test that will apply personalized medicine to kidney transplant patients to guide administration of immunosuppression with the aim of improving outcomes."
Related Shares:
Renalytix Plc